Sana Biotechnology (SANA) AI Stock Analysis

• Market Cap: $483.80M
• Dividend Yield: N/A
• Average Volume (3M): 3.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: 19.94%
• Country: US
• Employees: 194
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 225,024,900
• 10 Day Avg. Volume: 3,965,767
• 30 Day Avg. Volume: 3,001,144
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -2.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $9.50
• Price Target Upside: 292.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Sana Biotechnology's overall stock score reflects significant financial challenges and a bearish technical outlook. The company's lack of revenue and profitability, coupled with its reliance on external financing, are primary concerns. However, the promising results from its hypoimmune platform offer a potential upside if successfully developed, enhancing its industry positioning in the long term.

Positive Factors

Clinical Data

Sana Biotechnology reported positive 12-week survival data for HIP-edited hypoimmune donor-derived pancreatic islet cells, showing no safety issues and evasion of immune detection.

Financial Position

The company's cash position is strong with $152.5 million, suggesting financial stability and the ability to continue funding its research and development efforts.

Strategic Developments

Sana plans to submit an IND for an in-vivo CART program, which could be a significant development in B-cell driven autoimmune diseases and cancers.

Negative Factors

Clinical Limitations

Some investors note that the C-peptide levels were significantly lower than normal levels and therefore not enough for the patients to achieve insulin independence.

Operational Performance

The report of no revenues and higher-than-expected R&D and SG&A expenses might raise concerns about Sana's current operational performance.

Revenue and Expenses

Sana reported no revenues for 4Q24, with R&D and SG&A expenses higher than estimated.

Sana Biotechnology Business Overview & Revenue Model

Company Description

Sana Biotechnology (SANA) is a leading biotechnology company focused on developing and delivering engineered cells as medicines for patients. Operating within the biotechnology and pharmaceutical sectors, Sana specializes in advancing in vivo and ex vivo cell engineering platforms with the goal of treating a range of diseases including cancer, genetic disorders, and other serious illnesses. The company's core technologies aim to repair or control genes and replace damaged cells with healthy ones, offering innovative solutions that address unmet medical needs.

How the Company Makes Money

Sana Biotechnology makes money primarily through the development and commercialization of its proprietary cell engineering platforms and technologies. The company generates revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies. Additionally, Sana may earn revenue from government grants and research funding, as well as potential future sales of approved therapeutic products. Strategic collaborations and licensing agreements are significant contributors to Sana's earnings, enabling the company to leverage its innovative technologies for broader applications and market reach.

Sana Biotechnology Financial Statement Overview

Summary

Sana Biotechnology faces significant financial challenges with no revenue generation, operational losses, and negative cash flows. Although there are slight improvements in equity positions, the company relies heavily on external financing.

Income Statement

Sana Biotechnology shows significant losses with no revenue generation across all periods. The company exhibits a negative EBIT and EBITDA, which are reflective of its operational losses. The net profit margin is non-existent due to zero revenue, highlighting a challenging financial position.

Balance Sheet

The company's balance sheet shows a high level of debt relative to equity, particularly in earlier periods with negative equity which has improved over time. The equity ratio indicates a moderate reliance on equity financing, but the persistent losses erode shareholder value. The gradual improvement in stockholders' equity suggests some potential for stability.

Cash Flow

Operating cash flows are consistently negative, reflecting cash outflows that are not covered by revenue. Free cash flow is also negative, pointing to a reliance on external financing to sustain operations. Although there is some improvement in free cash flow, the overall cash flow situation remains precarious.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-15.18M	-30.86M	-27.73M	-17.91M	-10.17M	-3.92M
	EBIT
-296.71M	-326.90M	-272.56M	-356.91M	-286.15M	-141.15M
	EBITDA
-288.17M	-252.39M	-256.94M	-356.91M	-287.03M	-138.90M
	Net Income Common Stockholders
-305.81M	-283.25M	-266.39M	-344.18M	-278.64M	-130.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
138.98M	205.19M	434.01M	746.88M	412.00M	138.98M
	Total Assets
415.70M	565.30M	822.72M	1.13B	730.30M	415.70M
	Total Debt
48.21M	104.10M	108.25M	110.94M	71.91M	48.21M
	Net Debt
-31.82M	-29.42M	-68.51M	-142.09M	-340.09M	-31.82M
	Total Liabilities
558.24M	277.79M	323.40M	400.90M	1.15B	558.24M
	Stockholders Equity
-142.54M	287.51M	499.31M	728.50M	-421.18M	-142.54M
Cash Flow		Free Cash Flow
-274.99M	-273.61M	-310.93M	-280.92M	-161.85M	-111.69M
	Operating Cash Flow
-227.95M	-253.58M	-290.05M	-251.05M	-137.98M	-85.50M
	Investing Cash Flow
-14.32M	172.01M	210.56M	-245.80M	-252.56M	-87.86M
	Financing Cash Flow
200.82M	31.65M	4.91M	631.75M	435.69M	223.73M

Sana Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SANA, the sentiment is Negative. The current price of 2.42 is below the 20-day moving average (MA) of 2.54, below the 50-day MA of 2.92, and below the 200-day MA of 3.93, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 38.67 is Neutral, neither overbought nor oversold. The STOCH value of 18.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SANA.

Sana Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BEAM	50 Neutral	$2.40B	―	-43.94%	―	-83.18%	-144.95%
Sector *	49 Neutral	$6.90B	0.78	-53.24%	2.46%	20.86%	1.26%
ARCT	48 Neutral	$349.30M	―	-31.16%	―	-13.98%	-200.43%
CRSP	46 Neutral	$3.66B	―	-19.20%	―	-89.95%	-123.71%
EDIT	39 Underperform	$107.87M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$903.71M	―	-54.00%	―	59.55%	3.09%
SANA	37 Underperform	$483.80M	―	-99.17%	―	―	19.94%

Sana Biotechnology Corporate Events

Sana Biotechnology Shows Promise with Hypoimmune Platform

Sana Biotechnology announced promising results from its hypoimmune platform (HIP) that show potential in overcoming allogeneic and autoimmune rejection, notably in type 1 diabetes. The company’s approach, which addresses a significant limitation in transplant medicine, could transform treatment options for various diseases, enhancing its industry positioning and offering new hope for patients with unmet medical needs.